Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

SHE:300584 Revenue

Nanjing Hicin Pharmaceutical had revenue of 251.13M CNY in the quarter ending September 30, 2026, with 54.11% growth. This brings the company's total for the last twelve months to 814.80M, up 32.40% year-over-year. In the year 2025, Nanjing Hicin Pharmaceutical had annual revenue of 671.05M with 33.05% growth. That makes Nanjing Hicin Pharmaceutical the 21,150th largest company in the world by revenue and 3,889th in China.

• Revenue (ttm): 814.80M
• Revenue Growth: +32.40%
• P/S Ratio: 4.72
• Revenue / Employee: 1.47M
• Employees: 553
• Market Cap: 3.85B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• East China 256.82M 38.3%
• North China 187.39M 27.9%
• Southern China 64.35M 9.6%
• Central China Region 62.59M 9.3%
• Southwest Region 46.84M 7.0%
• Northwestern Region 29.86M 4.4%
• Northeast China Region 23.20M 3.5%

Fiscal year ended Dec 31, 2025 See the full SHE:300584 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	671.05M	166.69M	33.05%
Dec 31, 2024	504.36M	-13.47M	-2.60%
Dec 31, 2023	517.83M	-8.63M	-1.64%
Jan 1, 2023	526.47M	-51.85M	-8.97%
Jan 1, 2022	578.32M	-127.98M	-18.12%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error